Protein kinase inhibitors

MaaT Pharma Treats First Acute Myeloid Leukemia Patient in Phase 1 Clinical Trial to Evaluate Capsule Formulation of Microbiome Restoration Biotherapeutic

Retrieved on: 
Thursday, November 12, 2020
Oncology, Health, Other Science, Clinical trials, Pharmaceutical, Science, Blood disorders, Acute myeloid leukemia, Myelodysplastic syndrome, Cancer, 7+3, Clinical medicine, Leukemia, Protein kinase inhibitors, Hematology, Bemcentinib

The trial named CIMON will enroll patients with acute myeloid leukemia (AML) or high-risk Myelodysplastic Syndrome (MDS) following intensive chemotherapy.

Key Points: 
  • The trial named CIMON will enroll patients with acute myeloid leukemia (AML) or high-risk Myelodysplastic Syndrome (MDS) following intensive chemotherapy.
  • This in turn can result in multiple complications, some of them severe, especially for leukemia patients.
  • The MaaT033 capsule formulation is designed to restore the microbiome of patients that receive intensive chemotherapy and adds an important treatment modality to our portfolio of microbiome restoration therapeutics.
  • Initiating the clinical evaluation of our capsule formulation is an important milestone for MaaT Pharma, enabling us to expand our therapeutics pipeline with a complimentary product candidate to our MaaT013 biotherapeutic.

BerGenBio Presents Phase II Bemcentinib Combination Study in NSCLC at Annual SITC Meeting

Retrieved on: 
Wednesday, November 11, 2020
Cancer treatments, Clinical medicine, Medicine, Cancer immunotherapy, Tyrosine kinase receptors, AXL receptor tyrosine kinase, Protein kinase inhibitors, Breakthrough therapy, Orphan drugs, Bemcentinib, Pembrolizumab, Non-small-cell lung carcinoma

"Our findings from this interim analysis suggest that bemcentinib has potential to reverse acquired resistanceto checkpoint inhibitors among previously treated NSCLC patients by targeting AXL expressing macrophages and regulatory dendritic cells.

Key Points: 
  • "Our findings from this interim analysis suggest that bemcentinib has potential to reverse acquired resistanceto checkpoint inhibitors among previously treated NSCLC patients by targeting AXL expressing macrophages and regulatory dendritic cells.
  • These encouraging results support the further development of AXL inhibition as a means to extend the efficacy of immunotherapy in biomarker-selected NSCLC patients."
  • The combination of bemcentinib and pembrolizumab was overall shown to be well tolerated and clinically active in CPI-refractory composite AXL (cAXL) positive NSCLC.
  • Bemcentinib (formerly known as BGB324), is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme.

BerGenBio Presents Phase II Bemcentinib Combination Study in NSCLC at Annual SITC Meeting

Retrieved on: 
Wednesday, November 11, 2020
Cancer treatments, Clinical medicine, Medicine, Cancer immunotherapy, Tyrosine kinase receptors, AXL receptor tyrosine kinase, Protein kinase inhibitors, Breakthrough therapy, Orphan drugs, Bemcentinib, Pembrolizumab, Non-small-cell lung carcinoma

"Our findings from this interim analysis suggest that bemcentinib has potential to reverse acquired resistanceto checkpoint inhibitors among previously treated NSCLC patients by targeting AXL expressing macrophages and regulatory dendritic cells.

Key Points: 
  • "Our findings from this interim analysis suggest that bemcentinib has potential to reverse acquired resistanceto checkpoint inhibitors among previously treated NSCLC patients by targeting AXL expressing macrophages and regulatory dendritic cells.
  • These encouraging results support the further development of AXL inhibition as a means to extend the efficacy of immunotherapy in biomarker-selected NSCLC patients."
  • The combination of bemcentinib and pembrolizumab was overall shown to be well tolerated and clinically active in CPI-refractory composite AXL (cAXL) positive NSCLC.
  • Bemcentinib (formerly known as BGB324), is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme.

Rubius Therapeutics Presents Preclinical Data for Lead Red Cell Therapeutic™ Clinical Oncology Program, RTX-240, at the Society for Immunotherapy of Cancer’s Annual Meeting

Retrieved on: 
Monday, November 9, 2020
Antibody-drug conjugates, Immune system, Protein kinase inhibitors, Camidanlumab tesirine, Loncastuximab tesirine

RTX-240 is an allogeneic, off-the-shelf Red Cell Therapeutic that is engineered to mimic the human immune system by stimulating adaptive and innate immunity to generate an anti-tumor immune response.

Key Points: 
  • RTX-240 is an allogeneic, off-the-shelf Red Cell Therapeutic that is engineered to mimic the human immune system by stimulating adaptive and innate immunity to generate an anti-tumor immune response.
  • Rubius Therapeutics is currently enrolling patients in the Phase 1/2 clinical trial of RTX-240 for the treatment of patients with relapsed/refractory or locally advanced solid tumors.
  • In addition, RTX-240 is being evaluated in a second Phase 1 arm of the clinical trial for the treatment of patients with relapsed/refractory acute myeloid leukemia.
  • Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics.

Rubius Therapeutics Announces Dosing of First Patient with Relapsed/Refractory Acute Myeloid Leukemia in the Ongoing Phase 1/2 Clinical Trial of RTX-240

Retrieved on: 
Thursday, November 5, 2020
Cancer treatments, Cancer, 7+3, Leukemia, Chemotherapy, Antibody-drug conjugates, Lactams, Protein kinase inhibitors, Acute myeloid leukemia, CD135

The ongoing clinical study of RTX-240 has two Phase 1 arms, one in all solid tumors and the other in relapsed/refractory AML.

Key Points: 
  • The ongoing clinical study of RTX-240 has two Phase 1 arms, one in all solid tumors and the other in relapsed/refractory AML.
  • When NK cells are restored to their full anti-tumor potential, their cytolytic activity predicts a better long-term outcome for patients with AML.
  • AML is a rare and aggressive cancer of the blood and bone marrow, and is the most common form of acute leukemia in adults.
  • Rubius Therapeutics is enrolling patients in a Phase 1/2 open label, multicenter, multidose, first-in-human dose-escalation and expansion study of RTX-240.

ALK updates its full-year financial outlook

Retrieved on: 
Thursday, November 5, 2020
ALK, Anaplastic lymphoma kinase, Nasdaq Nordic, Nasdaq Copenhagen, Economy of Europe, ALK-Abelló, Companies, Protein kinase inhibitors

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that its preliminary results for Q3 is showing a 7% organic revenue growth, fuelled by a 52% increase in tablet sales.

Key Points: 
  • ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that its preliminary results for Q3 is showing a 7% organic revenue growth, fuelled by a 52% increase in tablet sales.
  • Therefore, the company is upgrading its earnings and cash flow outlook to DKK 350-400 million and approximately DKK 0, respectively, while narrowing its revenue growth outlook to around 8% organic growth.
  • ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma.
  • Headquartered in Hrsholm, Denmark, ALK employs around 2,400 people worldwide and is listed on Nasdaq Copenhagen.

Calithera Biosciences Announces Expansion of Ongoing Clinical Trial Evaluating Telaglenastat in Combination with palbociclib (IBRANCE®)

Retrieved on: 
Wednesday, November 4, 2020
Chemical compounds, Organic compounds, Breakthrough therapy, Protein kinase inhibitors, Piperazines, KRAS, Palbociclib, CDKN2A, Panitumumab, MEK inhibitor, Chemical compounds, Organic compounds, Breakthrough therapy, Protein kinase inhibitors, Piperazines, KRAS, Palbociclib, CDKN2A, Panitumumab, MEK inhibitor

There is a strong rationale to target KRAS and CDKN2A mutated tumors with the combination of palbociclib and telaglenastat, said Susan Molineaux, PhD, president and chief executive officer of Calithera.

Key Points: 
  • There is a strong rationale to target KRAS and CDKN2A mutated tumors with the combination of palbociclib and telaglenastat, said Susan Molineaux, PhD, president and chief executive officer of Calithera.
  • In the ongoing Phase 1/2 clinical trial (NCT03965845), encouraging efficacy and safety of the combination was observed in PDAC patients treated in the dose escalation phase of the trial.
  • The new cohort of the Phase 1/2 clinical trial will be evaluating the safety and anti-tumor activity of telaglenastat in combination with palbociclib in patients with advanced, metastatic PDAC whose tumors harbor mutations in both KRAS and CDKN2A.
  • The ongoing Phase 1/2 trial is currently enrolling patients with colorectal cancer and non-small cell lung cancer whose tumors harbor mutations in KRAS.

Novartis' MONALEESA-7 KISQALI® (ribociclib) study demonstrated statistically significant improvement in overall survival in pre- and perimenopausal women with HR+/HER2- advanced breast cancer

Retrieved on: 
Monday, November 2, 2020
Chemical compounds, Protein kinase inhibitors, Breast cancer, Cyclopentanes, Piperazines, Ribociclib, Cancer, Kathleen I. Pritchard, Risk factors for breast cancer

"Overall survival is considered a very important outcome in oncology clinical trials," said Dr. Nathaniel Bouganim, Medical Oncologist, McGill University Health Centre.

Key Points: 
  • "Overall survival is considered a very important outcome in oncology clinical trials," said Dr. Nathaniel Bouganim, Medical Oncologist, McGill University Health Centre.
  • "The new ribociclib data showing overall survival benefit in the most common type of breast cancer in young women is an exciting and significant step towards meeting the most urgent unmet need for these women."
  • "We are pleased to make yet another strong medical data announcement around KISQALI and its potential for overall survival benefit."
  • Canadian Breast Cancer Network and Rethink Breast Cancer.

Global Anaplastic Lymphoma Kinase (ALK) Inhibitors Market 2020-2024: Focus on First, Second & Third Generation ALK Inhibitors - ResearchAndMarkets.com

Retrieved on: 
Friday, October 30, 2020
Pharmaceutical, Health, Oncology, Tyrosine kinase receptors, Chemical compounds, ALK, Anaplastic lymphoma kinase, Piperidines, Protein kinase inhibitors, Organic compounds, Lymphoma, Crizotinib, ALK inhibitor

The "Global Anaplastic Lymphoma Kinase (ALK) Inhibitors Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Anaplastic Lymphoma Kinase (ALK) Inhibitors Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.
  • The anaplastic lymphoma kinase (ALK) inhibitors market is poised to grow by $2.96 bn during 2020-2024 progressing at a CAGR of 20% during the forecast period.
  • The reports on anaplastic lymphoma kinase (ALK) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • This study identifies by the presence of patient assistance programs as one of the prime reasons driving the anaplastic lymphoma kinase (ALK) inhibitors market growth during the next few years.

Aprea Therapeutics to Highlight Changing Treatment Paradigm in MDS as well as Development Pipeline Progress at Virtual R&D Day Today

Retrieved on: 
Friday, October 30, 2020
Lactams, Chemical compounds, Nucleosides, Triazines, Organic compounds, Myelodysplastic syndrome, Azacitidine, Acute myeloid leukemia, Tumors of the hematopoietic and lymphoid tissues, Drugs, Protein kinase inhibitors, Vadastuximab talirine

Discussion with review of Apreas Phase 3 Clinical program in MDS to be followed by Q&A.

Key Points: 
  • Discussion with review of Apreas Phase 3 Clinical program in MDS to be followed by Q&A.
  • The live webinar will begin at 1:00 pm Eastern Time and conclude at approximately 3:00 pm.
  • The Companys lead product candidate is eprenetapopt (APR-246), a small molecule in clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
  • A pivotal Phase 3 clinical trial of eprenetapopt and azacitidine for frontline treatment of TP53 mutant MDS is ongoing.